BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, Zhang H, Shi B, Jia J, Li Q, Wang H, Li Z. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2019;111:409-418. [PMID: 30203099 DOI: 10.1093/jnci/djy134] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Kang CH, Kim Y, Lee DY, Choi SU, Lee HK, Park CH. c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. Cancers (Basel) 2021;13:5738. [PMID: 34830894 DOI: 10.3390/cancers13225738] [Reference Citation Analysis]
2 Staudt RE, Carlson RD, Snook AE. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer Biology & Therapy 2022;23:127-33. [DOI: 10.1080/15384047.2022.2033057] [Reference Citation Analysis]
3 Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov 2019;9:1656-72. [PMID: 31727671 DOI: 10.1158/2159-8290.CD-19-0487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Reference Citation Analysis]
5 Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res 2020;32:263-70. [PMID: 32410803 DOI: 10.21147/j.issn.1000-9604.2020.02.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
7 Zhang ZZ, Wang T, Wang XF, Zhang YQ, Song SX, Ma CQ. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Pharmacol Res 2021;175:106036. [PMID: 34920118 DOI: 10.1016/j.phrs.2021.106036] [Reference Citation Analysis]
8 Xu B, Liu F, Liu Q, Shi T, Wang Z, Wu N, Xu X, Li L, Fan X, Yu L, Liu B, Wei J. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J Gastrointest Oncol 2020;11:1431-9. [PMID: 33457012 DOI: 10.21037/jgo-20-344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, Izadi S, Hassanzadeh A, Shirafkan N, Tahmasebi S, Khiavi FM. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 2021;12:81. [PMID: 33494834 DOI: 10.1186/s13287-020-02128-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
10 Khorasani ABS, Sanaei MJ, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. Int Immunopharmacol 2021;101:108260. [PMID: 34678690 DOI: 10.1016/j.intimp.2021.108260] [Reference Citation Analysis]
11 Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, Christ E, Weber D, Suchan M, Bukur T, Birtel M, Jahndel V, Mroz K, Hobohm K, Kranz L, Diken M, Kühlcke K, Türeci Ö, Sahin U. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 2020;367:446-53. [DOI: 10.1126/science.aay5967] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 37.0] [Reference Citation Analysis]
12 Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol 2021;18:473-87. [PMID: 33790428 DOI: 10.1038/s41571-021-00492-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
14 Kumari R, Ouyang X, Wang J, Xu X, Zheng M, An X, Li QX. Preclinical pharmacology modeling of chimeric antigen receptor T therapies. Curr Opin Pharmacol 2021;61:49-61. [PMID: 34619442 DOI: 10.1016/j.coph.2021.08.008] [Reference Citation Analysis]
15 Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, Jin MM. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Mol Ther Oncolytics 2020;18:587-601. [PMID: 32995483 DOI: 10.1016/j.omto.2020.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Qian S, Villarejo-Campos P, García-Olmo D. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. J Clin Med 2021;10:5050. [PMID: 34768570 DOI: 10.3390/jcm10215050] [Reference Citation Analysis]
17 Chandra R, Balachandar N, Wang S, Reznik S, Zeh H, Porembka M. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Ther 2021;28:390-9. [PMID: 33009508 DOI: 10.1038/s41417-020-00234-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Oh S, Yang H, Oh HR, Seo M, Lee C, Kim Y, Choi JY, Kim NY, Cheon GJ, Kang KW, Shin YK, Youn H. Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.04.003] [Reference Citation Analysis]
19 Faghfuri E, Shadbad MA, Faghfouri AH, Soozangar N. Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. Immunotherapy 2022. [PMID: 35232264 DOI: 10.2217/imt-2021-0285] [Reference Citation Analysis]
20 Chen C, Gu YM, Zhang F, Zhang ZC, Zhang YT, He YD, Wang L, Zhou N, Tang FT, Liu HJ, Li YM. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology 2021;10:1901434. [PMID: 33854821 DOI: 10.1080/2162402X.2021.1901434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Olnes MJ, Martinson HA. Recent advances in immune therapies for gastric cancer. Cancer Gene Ther 2021. [PMID: 33664460 DOI: 10.1038/s41417-021-00310-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ali AI, Oliver AJ, Samiei T, Chan JD, Kershaw MH, Slaney CY. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. Front Oncol 2019;9:56. [PMID: 30809507 DOI: 10.3389/fonc.2019.00056] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
23 Gan LL, Hii LW, Wong SF, Leong CO, Mai CW. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers (Basel) 2020;12:E1872. [PMID: 32664564 DOI: 10.3390/cancers12071872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
24 Mao R, Hussein MS, He Y. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. Expert Rev Mol Med 2022;24:e7. [PMID: 35086597 DOI: 10.1017/erm.2021.32] [Reference Citation Analysis]
25 Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188615. [PMID: 34403771 DOI: 10.1016/j.bbcan.2021.188615] [Reference Citation Analysis]
26 Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Sci Rep 2019;9:8420. [PMID: 31182754 DOI: 10.1038/s41598-019-44874-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
27 Yang H, Park H, Lee YJ, Choi JY, Kim T, Rajasekaran N, Lee S, Song K, Hong S, Choi JS, Shim H, Kim YD, Hwang S, Choi YL, Shin YK. Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting. Biomolecules 2019;10:E51. [PMID: 31905631 DOI: 10.3390/biom10010051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Rosenbaum MW, Gonzalez RS. Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology 2021;78:148-61. [PMID: 33382497 DOI: 10.1111/his.14244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kawazoe A, Shitara K. Next-generation sequencing and biomarkers for gastric cancer: what is the future? Ther Adv Med Oncol 2019;11:1758835919848189. [PMID: 31258627 DOI: 10.1177/1758835919848189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Liu H, Wu J, Xu X, Wang H, Zhang C, Yin S, He Y. Peritumoral TIGIT+CD20+ B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer. International Immunopharmacology 2022;108:108735. [DOI: 10.1016/j.intimp.2022.108735] [Reference Citation Analysis]
31 Wu J, Cai J. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Dig Dis Sci 2021;66:359-68. [PMID: 32140943 DOI: 10.1007/s10620-020-06183-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
32 Jeon J, Cheong JH. Clinical Implementation of Precision Medicine in Gastric Cancer. J Gastric Cancer 2019;19:235-53. [PMID: 31598369 DOI: 10.5230/jgc.2019.19.e25] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
33 Zhao X, Ning Q, Mo Z, Tang S. A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment. Artif Cells Nanomed Biotechnol 2019;47:3621-30. [PMID: 31468992 DOI: 10.1080/21691401.2019.1657875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Cao B, Liu M, Huang J, Zhou J, Li J, Lian H, Huang W, Guo Y, Yang S, Lin L, Cai M, Zhi C, Wu J, Liang L, Hu Y, Hu H, He J, Liang B, Zhao Q, Zhu K. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci 2021;17:3850-61. [PMID: 34671203 DOI: 10.7150/ijbs.64630] [Reference Citation Analysis]
35 Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. Front Immunol 2021;12:663201. [PMID: 33995389 DOI: 10.3389/fimmu.2021.663201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lu Y, Zhang J, Chen Y, Kang Y, Liao Z, He Y, Zhang C. Novel Immunotherapies for Osteosarcoma. Front Oncol 2022;12:830546. [DOI: 10.3389/fonc.2022.830546] [Reference Citation Analysis]
37 Zhao C, Rong Z, Ding J, Wang L, Wang B, Ding L, Meng L, Meng X, Wang F, Yang Z, Shou C, Zhu H. Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery. Mol Pharm 2022. [PMID: 35344359 DOI: 10.1021/acs.molpharmaceut.1c00947] [Reference Citation Analysis]
38 Huang F, Jiang J, Yao Y, Hu S, Wang H, Zhu M, Yu L, Liu Q, Jia H, Xu W. Circular RNA Hsa_circRNA_101996 promotes the development of Gastric Cancer via Upregulating Matrix Metalloproteinases-2/Matrix Metalloproteinases-9 through MicroRNA-143/Ten-eleven translocation-2 Pathway. J Cancer 2021;12:6665-75. [PMID: 34659556 DOI: 10.7150/jca.62121] [Reference Citation Analysis]
39 Bębnowska D, Grywalska E, Niedźwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Góźdź S, Roliński J, Polkowski W. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. J Clin Med 2020;9:E1894. [PMID: 32560392 DOI: 10.3390/jcm9061894] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
40 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: New roads; old destination. Transl Oncol 2021;14:101079. [PMID: 33862524 DOI: 10.1016/j.tranon.2021.101079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
41 Kyuno D, Takasawa A, Takasawa K, Ono Y, Aoyama T, Magara K, Nakamori Y, Takemasa I, Osanai M. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 2021;:1967080. [PMID: 34486479 DOI: 10.1080/21688370.2021.1967080] [Reference Citation Analysis]
42 Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Front Immunol 2021;12:687822. [PMID: 34093592 DOI: 10.3389/fimmu.2021.687822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Ilic D, Liovic M. Industry updates from the field of stem cell research and regenerative medicine in May 2020. Regenerative Medicine 2020;15:2045-51. [DOI: 10.2217/rme-2020-0090] [Reference Citation Analysis]
44 Lü P, Qiu S, Pan Y, Yu F, Chen K. Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers. Cancer Biother Radiopharm 2021;36:307-15. [PMID: 33481647 DOI: 10.1089/cbr.2020.4089] [Reference Citation Analysis]
45 Li J. Targeting claudins in cancer: diagnosis, prognosis and therapy. Am J Cancer Res 2021;11:3406-24. [PMID: 34354852] [Reference Citation Analysis]
46 Freitag F, Maucher M, Riester Z, Hudecek M. New targets and technologies for CAR-T cells. Curr Opin Oncol 2020;32:510-7. [PMID: 32657796 DOI: 10.1097/CCO.0000000000000653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]